IMM 1.45% 34.0¢ immutep limited

Ann: Immutep announces publication of ELCC 2022 abstract, page-41

  1. 25,472 Posts.
    lightbulb Created with Sketch. 1388
    note the wording in the last point paragraph QQ...

    • Important additional data on safety and efficacy including 6 months Overall Survival (OS), Tumour Growth
    Kinetics, and details of the confirmed partial responses will be presented in the poster at ELCC
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.